Chronic Rhinosinusitis: Making Treatment Decisions
Price: FREE for members and non-members
Session recorded on December 10, 2020
Speaker: Wesley Sublett, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this activity learners should be able to:
- Define chronic rhinosinusitis
- Discuss the evaluation tools utilized in CRS
- Evaluate medical treatments of CRS
- Evaluate surgical treatments of CRS
All identified conflicts of interest have been resolved.
Sally Schlosser, RN, Planner, Reviewer
Nothing to disclose
Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Wesley Sublett, MD, Speaker
Disclosures: Speaker/Honorarium/Clinical Investigator/Contracted Research: Astra Zeneca, DBV Technologies, Pfizer, Aimmune, ALK, Novartis, Regeneron, Optinose
Consultant/Consulting fees: Kaleo
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance